ST 266

Drug Profile

ST 266

Alternative Names: ST-266

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Noveome
  • Class Anti-inflammatories; Growth factors; Intercellular signalling peptides and proteins; Neuroprotectants; Proteins; Small molecules
  • Mechanism of Action Paracrine communication modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic conjunctivitis; Periodontitis
  • Phase I Burns; Dry eyes; Gingivitis
  • Preclinical Unspecified

Most Recent Events

  • 05 Dec 2016 Phase-II clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT02978183)
  • 15 Jun 2016 Phase-II clinical trials in Periodontitis (Adjunctive treatment) in USA (Topical) (NCT02761993; 9198071)
  • 19 Apr 2016 Preclinical trials in Periodontitis in USA (Topical) (Noveome pipeline, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top